Petersfield, Hampshire, 11th February 2026 — Aspire Pharma Limited, one of the UK’s fastest-growing specialty generics pharmaceutical businesses, has acquired Caragen, a Dublin based pharmaceutical organisation with a strong presence in hospital immunology therapies.
Caragen brings extensive commercial expertise in hospital-based medicines and medical devices alongside being a well-established distribution network serving the pharmaceutical, medical device and healthcare sectors throughout Ireland.
Under the acquisition, Aspire will acquire the Irish distribution rights to 100+ product lines covering a number of therapeutic areas including immunology, oncology, infectious diseases, and medical devices.
Richard Condon, Aspire Pharma Chief Executive, said:
“This acquisition strengthens Aspire’s existing portfolio, broadens our reach into new therapeutic areas and significantly enhances our capabilities in Ireland.
“It represents another key milestone in our growth journey and marks the beginning of a new phase of strategic international expansion, as we steadily build our European footprint. By advancing our commercial and technical capabilities in Ireland, we are proud to accelerate our ability to serve patients and deliver meaningful value to healthcare systems across Europe and beyond.”
From a commercial operations standpoint, Caragen will continue to operate as an independent brand in Ireland. The company’s senior management team and dedicated professionals will also remain in place, ensuring a smooth integration and effective knowledge transfer into the broader Aspire Pharma ecosystem.
Andrew O’Connell, Managing Director of Caragen, said:
“After building Caragen into a trusted partner for hospital-based therapies across Ireland, we are proud to be joining Aspire Pharma, which shares our commitment to quality, innovation and delivering the highest levels of patient care. We look forward to expanding and accelerating new product launches in current and new channels in Ireland.”
MAT-UK-COR-0070-1 | February 2026
